WallStreetZenWallStreetZen

NASDAQ: ITRM
Iterum Therapeutics PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ITRM stock forecasts and price targets.

Forecast return on equity

Is ITRM forecast to generate an efficient return?

Company
N/A
Industry
310.8%
Market
238.59%

Forecast return on assets

Is ITRM forecast to generate an efficient return on assets?

Company
N/A
Industry
115.15%

ITRM earnings per share forecast

What is ITRM's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.32
Avg 2 year Forecast
$0.06

ITRM revenue forecast

What is ITRM's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$9.6M+2,352.31%
Avg 2 year Forecast
$42.2M+10,713.33%
Avg 3 year Forecast
$49.7M+12,645.64%
ITRM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ITRM revenue growth forecast

How is ITRM forecast to perform vs Biotechnology companies and vs the US market?

Company
420.47%
Industry
118.19%
Market
23.42%
ITRM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ITRM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ITRM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ITRM$0.30N/AN/A
CASI$0.77$4.00+419.48%Buy
LEXX$0.64$1.50+135.11%Buy
TRAW$1.94$8.00+312.37%Buy
LIMN$0.60N/AN/A
View Top Biotech Stocks

Iterum Therapeutics Stock Forecast FAQ

What is ITRM's earnings growth forecast for 2026-2027?

(NASDAQ: ITRM) Iterum Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.82%.

Iterum Therapeutics's earnings in 2026 is -$26,961,000.On average, 4 Wall Street analysts forecast ITRM's earnings for 2026 to be -$16,691,464, with the lowest ITRM earnings forecast at -$19,658,132, and the highest ITRM earnings forecast at -$13,302,495.

In 2027, ITRM is forecast to generate $2,961,389 in earnings, with the lowest earnings forecast at -$21,210,089 and the highest earnings forecast at $28,822,073.

If you're new to stock investing, here's how to buy Iterum Therapeutics stock.

What is ITRM's revenue growth forecast for 2026-2028?

(NASDAQ: ITRM) Iterum Therapeutics's forecast annual revenue growth rate of 420.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.19%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.42%.

Iterum Therapeutics's revenue in 2026 is $390,000.On average, 4 Wall Street analysts forecast ITRM's revenue for 2026 to be $504,861,362, with the lowest ITRM revenue forecast at $452,812,710, and the highest ITRM revenue forecast at $554,270,630. On average, 4 Wall Street analysts forecast ITRM's revenue for 2027 to be $2,226,161,999, with the lowest ITRM revenue forecast at $1,194,532,388, and the highest ITRM revenue forecast at $3,303,452,952.

In 2028, ITRM is forecast to generate $2,623,969,948 in revenue, with the lowest revenue forecast at $2,521,033,974 and the highest revenue forecast at $2,701,145,534.

What is ITRM's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ITRM) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 115.15%.

What is ITRM's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: ITRM) Iterum Therapeutics's current Earnings Per Share (EPS) is -$0.71. On average, analysts forecast that ITRM's EPS will be -$0.32 for 2026, with the lowest EPS forecast at -$0.37, and the highest EPS forecast at -$0.25. In 2027, ITRM's EPS is forecast to hit $0.06 (min: -$0.40, max: $0.55).

What is ITRM's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ITRM) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.